Actively Recruiting
Association Between Residual Viable Tumor and Prognosis After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-small Cell Lung Cancer
Led by Guangdong Provincial People's Hospital · Updated on 2025-02-21
120
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying lung cancer patients with a specific mutation called EGFR in their tumors. This type of non-small cell lung cancer (NSCLC) can respond well to targeted treatments given before surgery to shrink tumors and improve outcomes. The study looks back at patient data to understand how the amount of remaining live tumor (residual viable tumor, RVT) after this treatment relates to survival. The goal is to confirm RVT's value as a marker for predicting patient prognosis and guiding future care. This observational study involves patients who received targeted therapy before surgery and then had their tumors removed. Researchers examine the percentage of RVT left after treatment and surgery to see how it affects two main outcomes: disease-free survival (time without cancer returning) and event-free survival (time until relapse or death). They plan to follow patients for up to three years after surgery to collect this information. Participants will have their medical records and pathology reports reviewed to assess RVT and survival outcomes. The study includes patients aged 18 to 80 years who were diagnosed with EGFR-mutated NSCLC, treated with neoadjuvant targeted therapy, and underwent surgery. Researchers will analyze this data to better understand how RVT can help predict long-term results and improve management strategies for patients with this lung cancer subtype.
CONDITIONS
Brief Title
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years old
- Diagnosed with EGFR-mutated non-small cell lung cancer
- Treated with neoadjuvant targeted therapy
- Undergoing definitive surgery
You will not qualify if you...
- History of prior chemotherapy, immunotherapy, or radiotherapy
- History of malignancy or lung surgery
- Missing key data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies based on treatment plan
Participants receive targeted therapy before surgery to shrink the tumor.
Visits occur as part of routine care; exact schedule varies
Duration - 1 day
Participants undergo definitive surgery to remove the tumor after neoadjuvant therapy.
1 surgical procedure (in-person)
Duration - Up to 3 years postoperatively
Participants are monitored for disease-free and event-free survival to assess prognosis after surgery.
Follow-up visits scheduled according to standard postoperative care
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
G
Guibin Qiao
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here